BVF Partners OVID Position
Exited4-Fund ConvergenceBVF Partners exited their position in Ovid Therapeutics Inc. (OVID) in Q3 2025, after holding the stock for 11 quarters.
The position was first reported in Q1 2023 and has been tracked across 11 quarterly 13F filings.
OVID is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Full company profile →Short Interest
4.6%
3.2 days to cover
BVF Partners OVID Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q3 2025 | Exited | 0 | -3,853,818 | $0 |
| Q2 2025 | Held | 3,853,818 | — | $1.3M |
| Q1 2025 | Held | 3,853,818 | — | $1.2M |
| Q4 2024 | Held | 3,853,818 | — | $3.6M |
| Q3 2024 | Held | 3,853,818 | — | $4.5M |
| Q2 2024 | Held | 3,853,818 | — | $3.0M |
| Q1 2024 | Decreased | 3,853,818 | -2,997,233 | $11.8M |
| Q4 2023 | Held | 6,851,051 | — | $22.1M |
| Q3 2023 | Held | 6,851,051 | — | $26.3M |
| Q2 2023 | Held | 6,851,051 | — | $22.5M |
| Q1 2023 | New | 6,851,051 | +6,851,051 | $17.7M |
Frequently Asked Questions
Does BVF Partners own OVID?
No. BVF Partners exited their position in Ovid Therapeutics Inc. (OVID) in Q3 2025. They previously held the stock for 11 quarters.
How many hedge funds own OVID?
4 specialist biotech hedge funds currently hold OVID, including EcoR1 Capital, RA Capital Management, Eventide Asset Management and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did BVF Partners first buy OVID?
BVF Partners's position in OVID was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is BVF Partners's OVID position increasing or decreasing?
BVF Partners completely exited their OVID position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
OVIDCompany Page →
All fund holders, insider trades, catalysts, and cash runway
BVF PartnersPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →